Previous 10 | Next 10 |
– Results show that single doses of STK-001 up to 30mg and multiple doses of 20mg were well-tolerated with no safety concerns related to the study drug – – A trend toward a reduction in convulsive seizure frequency was observed among patients treated with ...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the UBS G...
Stoke Therapeutics (STOK): Q1 GAAP EPS of -$0.46 misses by $0.02.Cash, cash equivalents and restricted cash of $267.7M.Press Release For further details see: Stoke Therapeutics EPS misses by $0.02
– Results presented at ARVO annual meeting confirm earlier preclinical findings and support the Company’s work to discover and develop the first potential disease modifying approach for the treatment of ADOA – – ADOA is the most common inherited opt...
Stoke Therapeutics (STOK) announces the authorization of its Clinical Trial Application ((CTA)) by the United Kingdom Medicines and Healthcare products Regulatory Agency ((MHRA)) to initiate a Phase 1/2a study (ADMIRAL) of STK-001 for the treatment of Dravet syndrome.STK-001 is a proprietary ...
– New ADMIRAL study complements ongoing U.S. studies and marks first step in global expansion of clinical development of STK-001 – – Study will evaluate safety and PK of multiple doses of STK-001 starting at 30mg; Enrollment and dosing anticipated to begin...
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at two upcoming...
– First patient dosed in the multiple ascending dose portion of Phase 1/2a MONARCH study of STK-001 in Dravet syndrome – – Preliminary safety and PK data from the single ascending dose portion of MONARCH still expected in H2 2021 – – ...
Today, we take our first in-depth look at a midcap concern targeting severe genetic diseases. Stoke Therapeutics has had a good run since coming public in June of 2019. Can it continue? A full analysis follows in the paragraphs below. For further details see: Sizing...
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the Barclays...
News, Short Squeeze, Breakout and More Instantly...
Stoke Therapeutics Inc. Company Name:
STOK Stock Symbol:
NYSE Market:
Stoke Therapeutics Inc. Website:
2024-06-16 20:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences: Goldma...
2024-05-16 08:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...